BAYRY Archives - Spark Newswire

3 minute read

Penny Stocks

AI To Revolutionize Clinical Trials And Diagnostics

September 22, 12:51 PM

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics.

AMGN

1 minute read

From Years to Months: How AI is Shaping the Landscape of Clinical Trials

By Vandana Singh

September 22, 7:49 AM

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These human studies, crucial to drug development, can take years and accrue costs in the billions.

AMGN

2 minute read

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless – Stocks To Watch

By Vandana Singh

September 12, 4:06 PM

According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for relief from

BAYRY

5 minute read

Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen’s $28B Horizon Deal: Today’s Top Stories

By Vandana Singh

August 28, 10:37 AM

Reuters

AMGN

2 minute read

German Pharma Firm Bayer’s New Parkinson’s Treatment Shows Promise: What the Phase 1 Trial Reveals

By Vandana Singh

August 28, 10:02 AM

Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields selectively ablate (remove body tissue surgically) heart tissue in

BAYRY

1 minute read

FDA Approves Regeneron Pharmaceuticals’ Higher Dose Of Eylea For Age-Related Blindness

By Vandana Singh

August 21, 8:37 AM

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),

BAYRY

2 minute read

Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema

By Vandana Singh

July 31, 9:43 AM

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to Eylea (aflibercept) injection, in diabetic

BAYRY

1 minute read

AstraZeneca’s Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer

By Vandana Singh

June 29, 1:39 PM

AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC) patients who had not received prior systemic therapy and were not

AZN